Literature DB >> 11215158

[Therapeutic efficacy of cyclosporin A in four cases of amyopathic dermatomyositis with rapidly progressive interstitial pneumonia].

Y Ozawa1, D Kurosaka, T Yokoyama, N Tajima.   

Abstract

OBJECTIVES: We investigated the clinical features of amyopathic dermatomyositis (ADM) with rapidly progressive interstitial pneumonia (IP), and the effectiveness of cyclosporin A (CsA) for IP.
METHODS: In our four patients who were accorded with the notion of amyopathic dermatomyositis proposed by Euwer and treated with CsA for IP, and eight reported patients for whom we could obtain details of the clinical course, we investigated the relationship between the clinical features of them at the start of CsA administration and the clinical effectiveness of CsA.
RESULTS: When we investigated the effectiveness of CsA in our four patients and eight reported patients, we could judge that effective cases were four and ineffective cases were eight. We compared the PaO2 at the start of CsA administration between effective and ineffective cases, the average PaO2 at the start of CsA administration was 65.7 mmHg in four effective cases, while it was 51.0 mmHg in eight ineffective cases. There was a statistically significant difference between the groups.
CONCLUSIONS: Because our results suggested that many ineffective cases were treated with CsA after they had developed severe respiratory failure, we think that CsA should be given to ADM patients with rapidly progressive IP before the progression of respiratory failure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11215158

Source DB:  PubMed          Journal:  Ryumachi        ISSN: 0300-9157


  4 in total

1.  Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis.

Authors:  Hua Cao; Tanvi N Parikh; Jie Zheng
Journal:  Clin Rheumatol       Date:  2009-03-18       Impact factor: 2.980

2.  Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.

Authors:  Eun Ha Kang; Ran Nakashima; Tsuneyo Mimori; Jinhyun Kim; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  BMC Musculoskelet Disord       Date:  2010-09-28       Impact factor: 2.362

3.  Amyopathic dermatomyositis complicated by pneumomediastinum.

Authors:  Randy Tang; Christian R Millett; Justin J Green
Journal:  J Clin Aesthet Dermatol       Date:  2013-03

4.  Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia.

Authors:  Takuya Kotani; Tohru Takeuchi; Shigeki Makino; Kenichiro Hata; Shuzo Yoshida; Koji Nagai; Daisuke Wakura; Takeshi Shoda; Toshiaki Hanafusa
Journal:  Clin Rheumatol       Date:  2011-02-23       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.